Press releases
Browse LEO Pharma’s global press releases intended for media.
Press releases issued by our local operating companies can be viewed on our market websites.
-
LEO Pharma convene dermatology experts in global initiative on skin health
LEO Pharma convene dermatology experts in global initiative on skin health Ballerup, January 5, 2022 – Dermatology experts including Key Opinion Leaders (KOLs), Patient Groups and industry gather…
-
Catherine Mazzacco is leaving the position as President and CEO of LEO Pharma
Catherine Mazzacco is leaving the position as President and CEO of LEO Pharma Ballerup November 30, 2021 – After more than two years of leading LEO Pharma through…
-
LEO Pharma successfully refinances loan facility
LEO Pharma successfully refinances loan facility Ballerup, November 15, 2021 – Today, LEO Pharma announced that it has successfully refinanced the company’s syndicated loan facility of total DKK…
-
LEO Pharma and Veeva Systems Partner for Patient-centric Digital Trials
LEO Pharma and Veeva Systems Partner for Patient-centric Digital Trials BALLERUP, DENMARK and PLEASANTON, CA — Sept. 29, 2021 — LEO Pharma, a global leader in medical dermatology,…
-
LEO Pharma and X-Chem Enter Into Discovery Research Agreement
LEO Pharma and X-Chem Enter Into Discovery Research Agreement Multi-target Collaboration to Focus on Identification of Novel Small Molecules for Anti-inflammatory Applications BALLERUP, Denmark, and WALTHAM, Mass., US;…
-
LEO Pharma delivered on strategic ambitions and showed resilience during COVID-19 pandemic in 2020
LEO Pharma delivered on strategic ambitions and showed resilience during COVID-19 pandemic in 2020 Ballerup, Denmark, March 23, 2021. LEO Pharma net sales recovered from COVID-19 impact during…
Media Inquiries
Head of Media
+4530502014
JEILK@leo-pharma.com
SVP, Head of Corporate Communications
+4529407016
ANMRN@leo-pharma.com
Media Manager
+4553748849
CHBUN@leo-pharma.com
About LEO Pharma
LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with breakthrough medicines in healthcare. We are committed to making a fundamental difference in people’s lives, and our broad portfolio of treatments serves close to 100 million patients in over 70 countries annually. Headquartered in Denmark, LEO Pharma has a team of 4,000 people worldwide. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. For more information, visit www.leo-pharma.com
Our press releases are intended for the media
To comply with applicable regulation, product-related press releases are removed from our website within three weeks of publication. They are available upon request. For updated information about clinical trials, please visit https://clinicaltrials.gov/.